Enovis (ENOV) Stock: Buy, Sell, or Hold?
ENOV - Enovis Corporation
$19.28
0.87 (4.73%)
▲
5d:
-0.62%
30d:
-21.91%
90d:
-8.71%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ENOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ENOV shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ENOV shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.99
Based on 2.7% avg growth
INTRINSIC VALUE TODAY
$16.76
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ENOV is currently trading at $19.28, which is considered oversold relative to its 30-day fair value range of $20.84 to $27.82. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.0) compared to its historical average (6.4). Remarkably, the market is currently pricing in an annual earnings decline of 8.2% over the next few years. This pessimistic expectation contrasts with the company's recent 153.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ENOV is showing sideways momentum. Immediate support is located at $18.08, while resistance sits at $25.38. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $38.33 (+108.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENOV is showing sideways momentum. Immediate support is located at $18.08, while resistance sits at $25.38. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $38.33 (+108.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$20.84 -
$27.82
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 108.2% below Wall St target ($38.33)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$20.84 -
$27.82
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$18.08
Resistance Level
$25.38
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.99
Wall Street Target
$38.33
(+108.2%)
Revenue Growth (YoY)
3.2%
Earnings Growth (YoY)
153.1%
Profit Margin
-48.0%
Valuation Discount vs History
-8.2% cheaper
PE vs Historical
5.0 vs 6.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.2%
(market-implied from PE analysis)
1-Year Target
$16.90
(-8%)
2-Year Target
$15.51
(-16%)
3-Year Target
$14.24
(-23%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$18.28
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 1.4%)
$77.76
(+322%)
Base:
(SPY PE: 5.0, Growth: 1.4%)
$19.22
(+4%)
Bear:
(PE: 4.2, Growth: 1.4%)
$16.34
(-11%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.0 to 6.4
Stabilization Target:
$23.63
(+28.4%)
PE Expansion Potential:
+28.4%
Share & Embed Analysis
Last updated: September 11, 2026 4:07 PM ET
Data refreshes hourly during market hours. Next update: 5:07 PM
Data refreshes hourly during market hours. Next update: 5:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$108 | 50 HOLD |
